G-quadruplexes represent a platform with unique capacity to unify targeting and therapy, offering a promising alternative to antibody-based systems. However, issues such as structural polymorphism, pharmacokinetics, and controlled drug release must be addressed through rational design and chemical modification to fully translate these delivery systems into clinically relevant anticancer therapeutics.
Domínguez et al. (Tue,) studied this question.